Currently, there are 5.1 million people with Alzheimer’s disease in the United States and 13 million worldwide. In 30 years, AD is expected to affect 13 million in the US, and more than 100 million worldwide. The cost of care for AD in the US is currently estimated at $267 billion and this will balloon to more than $1 trillion per year by 2050 if new interventions are not developed. A deeper understanding of the AD therapeutic pipeline and the advances in trial methods may contribute to the development of novel and effective AD therapies in the future.
more at: https://www.pharmavoice.com/therapeutic-digests/alzheimers-disease/
